A groundbreaking study published in The Journal of Allergy and Clinical Immunology has identified a novel biomarker that could revolutionize the way severe drug allergies are predicted and managed. Researchers from the University of Oxford and Harvard Medical School collaborated on a multi-center trial involving over 1,200 patients with a history of drug hypersensitivity reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). The study focused on a specific cytokine signature—interleukin-15 (IL-15) in combination with granzyme B—that appears in the bloodstream up to 48 hours before the onset of severe cutaneous adverse reactions (SCARs).
The research team utilized machine learning algorithms to analyze blood samples from patients who had experienced SCARs in response to common medications such as antibiotics (e.g., penicillin, sulfonamides), anticonvulsants (e.g., carbamazepine), and allopurinol. They found that elevated levels of IL-15 and granzyme B were consistently present in patients who progressed to life-threatening reactions, whereas those with mild rashes did not exhibit the same pattern. This discovery is particularly significant because current diagnostic tools, such as skin patch testing and lymphocyte transformation tests, are often inconclusive or require weeks to yield results.
One of the most promising applications of this biomarker is in preemptive screening for high-risk patients. For example, individuals of Han Chinese descent are known to have a genetic predisposition (HLA-B*15:02) to carbamazepine-induced SJS. By incorporating IL-15/granzyme B testing into routine pre-prescription protocols, clinicians could identify susceptible patients before administering potentially dangerous drugs. Pharmaceutical companies are already exploring companion diagnostics that could be co-packaged with high-risk medications, similar to how genetic testing is used for abacavir in HIV treatment.
However, challenges remain in implementing this technology widely. The biomarker test requires specialized laboratory equipment and trained personnel, which may not be available in low-resource settings. Additionally, false positives could lead to unnecessary avoidance of first-line therapies. Despite these hurdles, the study represents a major leap forward in personalized medicine for drug allergies, offering hope for preventing catastrophic reactions that claim thousands of lives annually.
You Might Be Interested In:
- What Is the 5 Most Common Fruit Allergy?
- What Are the 4 Most Common Fall Allergies?
- What Are the 5 Most Common Skin Allergies?
